Copyright © 2013-2018 Ascletis Pharma Inc. All rights reserved.
Home

News & Events

Investor

Careers

Pipeline

Partnership

About  Us

About Us

Our Science

OurScience Pipeline Partership Investor Careers
Contact
Contact    Home

Innovating for a healthier life

Target

Indication

    Drug

Candidate

Pre-clinical

 NS3/4A

HCV

HCV

ASC21

Field

HCV

HBV

HIV

Undisclosed

Liver

Cancer

NASH

Protease

 NS5B

 NS5A

Cancer

VEGF&KSP

Undisclosed

Anti-viral

Fatty Liver

Disease

Danoprevir

Ravidasvir

ASC06

ASC09

Lead

Identification

Lead

Identification

Phase I

Commercial

     Rights

Launch

Licensed

  From

Roche

Presidio

Alnylam

Medivir

In-house

Janssen

In-house

Greater

China

Global

PRC

and Macau

Global

Greater

China

Greater

China

Greater

China

Phase III

Phase II

NDA Filing

Overview

Ravidasvir

Ganovo

Ravidasvir Ganovo

ASC06

ASC09

ASC06 ASC09
PIPELINE